MKP-1 Knockout Does not Prevent Glucocorticoid-Induced Bone Disease in Mice

详细信息    查看全文

• 作者：1. Division of Endocrinology ; Department of Medicine ; Faculty of Health Sciences ; Stellenbosch University ; Francie van Zijl Drive ; Tygerberg ; Cape Town ; 7505 South Africa2. Karlsruhe Institute of Technology ; Institute of Toxicology and Genetics ; Eggenstein-Leopoldshafen ; Germany
• 关键词：MKP ; 1 – ; ERK – ; Osteoblast – ; Glucocorticoid – ; Osteoporosis
• 刊名：Calcified Tissue International
• 出版年：2011
• 出版时间：September 2011
• 年：2011
• 卷：89
• 期：3
• 页码：221-227
• 全文大小：257.1 KB
• 参考文献：1. Canalis E, Mazziotti G, Giustina A, Bilezekian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319–1328
  2. Weinstein RS (2008) Glucocorticoid-induced osteoporosis. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. ASBMR, Washington, pp 267–272
  3. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137
  4. O’Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, Stewart SA, Manolagas SC, Weinstein RS (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induces their apoptosis and reduce bone formation and strength. Endocrinology 145:1835–1841
  5. Engelbrecht Y, de Wet H, Horsch K, Langeveldt CR, Hough FS, Hulley A (2003) Glucocorticoids induce rapid up-regulation of mitogen-activated protein kinase phosphatase-1 and dephosphorylation of extracellular signal-regulated kinase and impair proliferation in human and mouse osteoblast cell lines. Endocrinology 144:412–422
  6. Horsch K, de Wet H, Schuurmans MM, Allie-Reid F, Cato AC, Cunningham J, Burrin JM, Hough FS, Hulley PA (2007) Mitogen-activated protein kinase phosphatase-1/dual specificity phosphatase-1 mediates glucocorticoid inhibition of osteoblast proliferation. Mol Endocrinol 21:2929–2940
  7. Hulley PA, Gordon F, Hough FS (1998) Inhibition of MAPK activity and proliferation of an early osteoblast cell line (MBA-15.4) by dexamethasone: role of protein phosphatases. Endocrinology 139:2423–2431
  8. Hulley PA, Conradie MM, Langeveldt CR, Hough FS (2002) Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 31:220–229
  9. Conradie MM, de Wet H, Kotze DD, Burrin JM, Hough FS, Hulley PA (2007) Vanadate prevents glucocorticoid-induced apoptosis of osteoblasts in vitro and osteocytes in vivo. J Endocrinol 195:229–240
  10. Boutros T, Chevet E, Metrakos P (2008) Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death and cancer. Pharmacol Rev 60:261–310
  11. Patterson KI, Brummer T, O’Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418:475–489
  12. Farooq A, Zhou M (2004) Structure and regulation of MAPK phosphatases. Cell Signal 16:769–779
  13. Hendriks WJAJ, Elson A, Harroch S, Stoker AW (2008) Protein tyrosine phosphatases: functional inferences from mouse models and human disease. FEMS J 275:816–830
  14. Goldner JA (1938) A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14:237–242
  15. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610
  16. Ogawa A, Johnson JH, Ohneda M, McAllister CT, Inman L, Alam T, Unger RH (1992) Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes. J Clin Invest 90:497–504
  17. Bogoyevitch MA, Court NW (2004) Counting on mitogen-activated protein kinases—ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16:1345–1354
  18. Murphy LO, Blenis J (2006) MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31:268–275
  19. Marshall CJ (1995) Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179–185
  20. Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK (2007) Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 22(7):951–959
  21. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, Karsenty G, Franceschi RT (2000) MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor cbfa1. J Biol Chem 275(6):4453–4459
  22. Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E (2003) Multiple signaling pathways converge on the cbfa1/runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res 44:109–116
  23. Ge C, Xiao G, Franceschi RT (2007) Critical role of the extracellular signal-regulated kinase–MAPK pathway in osteoblast differentiation and skeletal development. J Cell Biol 176(5):709–718
  24. Higuchi CA, Myoui N, Hashimoto K, Kuriyama K, Yoshioka H, Itoh K (2002) Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 17:1785–1794
  25. Nakayama KY, Tamura M, Suzawa S, Harada S, Fukumoto S, Kato M, Miyazono, K, Rodan GA, Takeuchi Y, Fujita T (2003) Receptor tyrosine kinases inhibit bone morphogenetic protein-smad responsive promoter activity and differentiation of MC3T3-E1 osteoblast like cells. J Bone Miner Res 18:827–835
  26. Datta NS, Chen C, Berry JE, McCauley LK (2005) PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res 20(6):1051–1064
  27. Datta NS, Kolailat R, Fite A, Pettway G, Abou-Samra AB (2010) Distinct roles for mitogen-activated protein kinase phosphatase-1 (MKP-1) and ERK-MAPK in PTH1R signaling during osteoblast proliferation and differentiation. Cell Signal 22:457–466
  28. Waterman H, Yarden Y (2001) Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett 490:142–152
  29. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O’Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68(20):8322–8332
  30. Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM (1995) Negative feedback regulation and desensitization of insulin and epidermal growth factor-stimulated p21 ras activation. J Biol Chem 270:25320–25323
  31. Donovan S, Shannon KM, Bollag G (2002) GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 160:23–45
  32. Camps M, Nichols A, Arkinstall S (2000) Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 14:6–16
  33. Dickinson RJ, Keyse SM (2006) Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119:4607–4614
  34. Qin L, Li X, Ko J, Partridge NC (2005) Parathyroid hormone uses multiple mechanisms to arrest the cell cycle progression of osteoblastic cells from G1 to S phase. J Biol Chem 280(4):3104–3111
  35. Homme M, Schmitt CP, Mehls O, Schaefer F (2004) Mechanisms of mitogen-activated protein kinase inhibition by parathyroid hormone in osteoblast-like cells. J Am Soc Nephrol 15:2844–2850
  36. Aghaloo TL, Pirih FQ, Shi A, Bezouglaia O, Tetradis S (2006) Parathyroid hormone induces mitogen-activated kinase phosphatase 1 in murine osteoblasts primarily through cAMP-protein kinase A signaling. Periodontol 77:21–30
  37. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR (2006) Anti-inflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203(8):1883–1889
  38. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R (1996) Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAPkinase activity in ERP/MKP-1 deficient fibroblasts. Oncogene 13(5):925–931
  39. Sakaue H, Ogawa W, Nakamura T, Mori T, Nakamura K, Kasuga M (2004) Role of MAPK phosphatase-1 (MKP-1) in adipocyte. J Biol Chem 279(38):39951–39957
  40. Bazuine M, Carlotti F, Tafrechi RS, Hoeben RC, Maassen JA (2004) Mitogen-activated protein kinase (MAPK) phosphatase-1 and -4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 18(7):1697–1707
  41. Zhou Y, Ling ED, Dheen ST (2007) Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J Neurochem 102(3):667–678
  42. F眉rst R, Schroeder T, Eilken HM, Bubik MF, Kiemer AK, Zahler S, Vollmar AM (2007) MAPK phosphatase-1 represents a novel anti-inflammatory target of glucocorticoids in human endothelium. FASEB J 21(1):74–80
  43. Maier JV, Brema S, Tuckermann J, Herzer U, Klein M, Stassen M, Moorthy A, Cato AC (2001) Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 21:2663–2671
  44. Kassel O, Sancono A, Kr盲tzschmar J, Kreft B, Stassen M, Cato AC (2001) Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J 20(24):7108–7116
  45. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T (2006) Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176:1899–1907
  46. Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK, Bennett AM (2006) Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet induced obesity. Cell Metab 4(1):61–73
• 作者单位：http://www.springerlink.com/content/u155u800018x842l/
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Biochemistry
  Endocrinology
  Orthopedics
  Cell Biology
  
• 出版者：Springer New York
• ISSN：1432-0827

文摘

Glucocorticoid-induced osteoporosis (GCOP) is predominantly caused by inhibition of bone formation, resulting from a decrease in osteoblast numbers. Employing mouse (MBA-15.4) and human (MG-63) osteoblast cell lines, we previously found that the glucocorticoid (GC) dexamethasone (Dex) inhibits cellular proliferation as well as activation of the MAPK/ERK signaling pathway, essential for mitogenesis in these cells, and that both these effects could be reversed by the protein tyrosine phosphatase (PTP) inhibitor vanadate. In a rat model of GCOP, the GC-induced changes in bone formation, mass, and strength could be prevented by vanadate cotreatment, suggesting that the GC effects on bone were mediated by one or more PTPs. Employing phosphatase inhibitors, qRT-PCR, Western blotting, and overexpression/knockdown experiments, we concluded that MKP-1 was upregulated by Dex, that this correlated with the dephosphorylation of ERK, and that it largely mediated the in vitro effects of GCs on bone. To confirm the pivotal role of MKP-1 in vivo, we investigated the effects of the GC methylprednisolone on the quantitative bone histology of wild-type (WT) and MKP-1 homozygous knockout (MKP-1−/−) mice. In WT mice, static bone histology revealed that GC administration for 28 days decreased osteoid surfaces, volumes, and osteoblast numbers. Dynamic histology, following time-spaced tetracycline labeling, confirmed a significant GC-induced reduction in osteoblast appositional rate and bone formation rate. However, identical results were obtained in MKP-1 knockout mice, suggesting that in these animals upregulation of MKP-1 by GCs cannot be regarded as the sole mediator of the GC effects on bone.